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Background: Shivering is a very common complication in the postanesthesia period. Increasing studies have
reported ondansetron may be effective in prevention of postanesthesia shivering (PAS). However, the results
remained controversial; hence we conducted a meta-analysis of randomized controlled trials to evaluate the efficacy
and safety of ondansetron on the prevention of postanesthesia shivering.
Methods: PubMed and Embase databases were searched to identify the eligible randomized controlled trials assessing
the effect of ondansetron on the prevention of PAS. Results were expressed as risk ratios (RRs) with accompanying 95%
confidence intervals (CIs). The meta-analysis was performed with fixed-effect model or random-effect model according
to the heterogeneity.
Results: Six trials including 533 subjects were included. Compared with placebo, ondansetron was associated with a
significant reduction of PAS (RR 0.43, 95% CI, 0.27-0.70), without an increased risk of bradycardia (RR 0.37, 95% CI,
0.12-1.15). Compared with meperidine, no difference was observed in the incidence of PAS (RR 0.68, 95% CI, 0.39-1.19)
and bradycardia (RR 2.0, 95% CI, 0.38-10.64).
Conclusions: Ondansetron has a preventive effect on PAS without a paralleled side effect of bradycardia.
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Shivering, a very common complication of surgery owing
to postoperative pain and postanesthesia hypothermia, is
distressing for both patients and clinicians [1]. It can be
defined as involuntary and oscillatory muscular activities
that increase the metabolic rate by two to three folds to
maintain the core temperature, with the increment of
heat production by only 200% in adults [2]. Both neuraxial
(epidural and spinal anesthesia) and general anesthesia are
associated with a significant incidence of shivering, and
the incidence is 40%-60% in regional anesthetic patients
[3] and up to 60% in general anesthetic ones [4]. Shivering
can be associated with severe adverse effects by increasing
the oxygen consumption and carbon dioxide retention. It
can cause arterial hypoxia, increase cardiac output and the* Correspondence: suguangzhu@163.com
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unless otherwise stated.risk of myocardial ischemia. Besides, the movement of
shivering interferes with the electrocardiogram, blood
pressure, and pulse oximetry [5].
Recent years, with increasing awareness of its undesir-
able aftermath, effective prevention of postanesthesia
shivering (PAS) is being imperative. It has been reported
that PAS could be prevented by warming skin-surface
[6] and warming the administered fluid [7,8], but it is not a
perfect way. Many drugs have been shown to be effective
on prevention of PAS, such as opioids, α2-agonist, anti-
cholinergic, CNS stimulant, corticosteroid [9], however, few
of them were recommended for the prevention of PAS due
to various side-effects. For instance, Clonidine, a partial α2
adrenergic agonist, is related to bradycardia, hypotension
and sedation [10].
Ondansetron, a 5-TH3 receptor antagonist, is widely
used to prevent postoperative and pregnancy nausea and
vomiting. 5-TH can affect the body temperature and
shivering in rats since the balance of nor-epinephrineThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The flow chart of study selection.
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hypothalamus controls the temperature set point [11,12].
Consistently, several studies [3,13-16] have demonstrated
ondansetron can prevent PAS, which made ondansetron a
promising drug for postoperative complications including
PAS, nausea and vomiting. However, a later-day, large-
sample study conducted by Browning et al. [17] presented
that ondansetron did not prevent PAS among women
undergoing combined spinal and epidural anesthesia for
cesarean delivery. To our knowledge, there is no meta-
analysis to identify the precise effect of ondansetron on
the PAS, therefore, we performed a systematic review and
meta-analysis of randomized controlled trials to evaluate
and quantify the preventive effect of ondansetron on PAS.
Otherwise we also compared ondansetron with meperi-
dine about the effect on PAS and adverse effects.
Methods
Literature search and study selection
Potentially relevant studies were identified by searching
PubMed and Embase databases through July 2013 with
the terms of “ondansetron” and “shivering”. No limitation
was applied. In addition, reference lists from identified ci-
tations and relevant reviews were manually searched for
additional studies. Inclusion criteria for this meta-analysis
were as follows: (1) the objects underwent a surgical oper-
ation under the neuraxial anesthesia or general anesthesia;
(2) the comparison was between ondansetron and placebo
or meperidine about the preventive efficacy of PAS; (3)
the incidences of PAS were reported in both placebo and
ondansetron groups; (4) the study design was randomized
clinical trial. No minimum sample sizes were considered
for inclusion of studies in the analysis. The disaccords
were resolved by discussion.
Data extraction and quality assessment
Data (patient characteristics, surgical setting, anesthetic
type, mean core temperature (°C) at baseline, time of
drug administration, definition of PAS, and incidence of
PAS) was collected individually by two reviewers. Data was
extrapolated from figures as needed. The qualities of the
included studies were evaluated by the Jadad scale with the
full score of five points. In addition to the primary outcome
of PAS; the adverse effects were also extracted from the in-
cluded studies if possible. Any dispute was resolved by
discussion.
Statistical analysis
The main analysis was focused on the association between
ondansetron and PAS, and subgroup analyses stratified by
type of anesthesia and dosage of ondansetron were also
conducted. Since three included studies [13-15] investi-
gated the prophylactic effect of meperidine on PAS, wealso compared ondansetron and meperidine on PAS, and
the adverse effects were also explored when available.
Either fixed-effect model or random-effect model was
used according to the heterogeneity. Heterogeneity was
evaluated by Q statistic (a significant level of P<0.1) and I2
statistic (greater than 50% as evidence of a significant
level). A two-tailed P valueless than 0.05 represents statis-
tical significance in all tests except the specific condition
where a P value was declared. All statistical analyses were
performed with Stata 12.0 software (StataCorp, College
Station, TX, USA).
Results
114 potential studies (PubMed 17, EMBASE 97) were ob-
tained. The detailed screening flow was shown in Figure 1.
After screening the titles and abstracts, 103 studies were ex-
cluded because they were duplicates or did not provide
available data. Five studies were excluded by full-text
screening, of which two [18,19] were duplicates, two [20,21]
aimed to investigate the therapeutic effect of ondansetron
on PAS, the other one [22] was to determine the effect of
ondansetron on threshold of shivering. Detailed characteris-
tics of 6 included studies in this meta-analysis are presented
in Table 1.
Totally 533 subjects were involved in the 6 included
trials, of which 235 received ondansetron, 213 received a
placebo, and 85 received meperidine. The dosage of ondan-
setron was either 4 mg or 8 mg in individual study, and me-
peridine was 0.4 mg/kg in all the three studies [13,15,18].
The trial drugs were all given before anesthesia, but one
[17] at the end of the surgery.
The pooled estimate suggested that ondansetron had a
potential effect on the prevention of PAS (RR = 0.43,
95% CI, 0.27-0.70) (Figure 2), with a moderate evidence
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Figure 2 The pooled estimate of the 6 included studies by random effect model.
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group analyses were showing in Table 2, and all demon-
strated that ondansetron was associated with a significant
reduction of PAS risk.
Additionally, the adverse effect and comparison with me-
peridine of ondansetron were analyzed with a limited test
power. Compared to placebo, no significant association of
ondansetron with bradycardia was found (RR = 2.00, 95%,
0.38-10.64). Significant differences of ondansetron were
also not observed in PAS (RR = 0.68, 95% CI, 0.39-1.19)
and bradycardia (RR = 2.0, 95% CI, 0.38-10.64) by compari-
son with meperidine (Figures 3 and 4).Discussion
According to our findings, compared with placebo, ondan-
setron could reduce the prevalence of PAS from 49.3%
(placebo) to 23.4% without increased risk of bradycardia.
However, No superiority was observed in ondansetron over
meperidine on the effect of antishivering and incidence of
bradycardia.
Serotonin system plays an important role in the thermo-
regulation. The mechanisms of ondansetron on PAS may
be related to a central mechanism of the inhibition ofTable 2 Results of subgroup analysis by dosage of
ondansetron and anesthetic techniques
Group No. of
studies
Relative risk I2 Pheterogeneity Effect
model
Dosage
4 mg 3 0.36 (0.22, 0.58) 40.7 0.185 Fixed
8 mg 3 0.47 (0.25, 0.90) 66.0 0.032 Random
Anesthetic technique
General 3 0.40 (0.27, 0.60) 0 0.559 Fixed
Spinal 2 0.23 (0.10, 0.52) 0 0.949 Fixed5-HT reuptake on the preoptic anterior hypothalamic re-
gion [15]. It was proven that 5-HT3 agonist could in-
duce hyperthermia, and its antagonist could lead to
hypothermia [23,24]. However, in healthy volunteers, the
core-temperature thresholds triggering shivering did not
change under comparison with placebo [22]. Several stud-
ies [15,16,25] have proven that core-to-peripheral redistri-
bution of body temperature after the general anesthetics is
characterized by 1 decrease in the core temperature at the
first 20 to 30 minutes, and this alteration kept similar in
ondansetron group [15,16]. The evidences above sug-
gested that the effect of ondansetron on the prevention of
PAS is irrelevant to the core hypothermia. On the con-
trary, Kelsaka et al. [15] found that the core temperature
was preserved in ondansetron group rather than placebo,
but no one shared the same idea with them. So there is lit-
tle evidence supporting preserving the temperature to be
another antishivering mechanism.
Shivering differs from general anesthesia to neuraxial
anesthesia. General anesthesia could impair the central
thermoregulation, while neuraxial anesthesia impairs
both central and peripheral thermoregulation, by enlar-
ging interthreshold range via raising the sweating thresh-
old and decreasing the vasoconstriction and shivering
thresholds [26]. The core temperature decrease will be
in a plateau after 3-4 h in general anesthesia but no plat-
eau appears in the neuraxial anesthesia, because the vaso-
constriction will be evoked when the core temperature
triggers the reset vasoconstriction threshold in general
anesthesia but not neuraxial anesthesia [2]. Thus, more
heat will be lost, and more incidences will occur in neur-
axial anesthesia. However, in our analysis, there was no
difference in the risks of PAS between general and neurax-
ial anesthesia. It might be explained by short duration of
the operation, and limited sample sizes, different heat
preservation measures after operation.
Figure 3 The antishivering effect of ondansetron comparing with meperdine.
Tie et al. BMC Anesthesiology 2014, 14:12 Page 5 of 7
http://www.biomedcentral.com/1471-2253/14/12As for dose-dependent effect of ondansetron on shiv-
ering, Powell et al. [16] found that ondansetron was as-
sociated with a dose-dependent reduction in shivering,
while the effect was not observed in pooled effect. As we
can see the incidence of shivering was 10% in people
weighed about 52 kg with low-dose ondansetron (4 mg)
used [15], but Powell et al. [16] found the incidence was
8% in people weighed about 76 kg with high-dose
ondansetron(8 mg). So we presume the various weights
of the subjects might mask the dose-dependent effect.
When compared to other drugs, ondansetron is absent
from the hemodynamic effect in the treatment and pre-
vention of PAS [15,26,27], which contributes much to its
safety. Thus, the result that no difference exists in brady-
cardia between ondansetron and placebo is acceptable
despite a limited sample. Additionally, two fresh studies
demonstrated ondansetron is safe for pregnant women
and fetus [28,29]. Apart from the primary outcome ofFigure 4 The side effects of bradycardia of ondansetron by comparinPAS and side effect of bradycardia, other side effects were
also mentioned but were not appropriate for quantitative
analysis, among which none indicated a significant risk of
convulsion, myoclonus, rush, pruritus, headache, pain,
hypotension, sedation, nausea or vomiting.
Meperidine has a therapeutic effect on PAS, and its
mechanism is likely to be associated with activation of κ
receptor [30-32]. In our meta-analysis, we compared the
effect of meperidine and ondansetron on the prevention
of PAS, no significant superiority was found in ondanse-
tron. While taking the adverse effects into consider-
ation, accumulating studies show that meperidine could
increase the incidence of nausea and vomiting [30,31]
and induce respiratory depression [16]. Like ondanse-
tron, meperidine at dose of 0.4 mg/kg for treatment of
PAS rarely causes cardiovascular effects, which were
also poorly confirmed by our combined estimate with
small sample.g with meperdine.
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PAS have been found. Physostigmine inhibits PAS through
cholinergic system, but it would also cause nausea and
vomiting, increased heart rate and blood pressure [33].
Tramadol, which could inhibit 5HT-uptake and increase
its release, reduces PAS after general anesthesia [34]. In
contrast to ondansetron, it could depress the thresholds of
sweating, vasoconstriction and shivering [35]. Doxapram,
used as a stimulant in respiratory failure, had been proven
to be effective on PAS, but accompanied with distinct side
effect on hemodynamics [14]. From our analysis and the
comparisons, ondansetron exhibited a high safety profile.
Study by Browning et al. [17], which found ondansetron
could not reduce the incidence of shivering, contributed
to the heterogeneity as identified by forest plots and sensi-
tive analysis. The subgroup analysis also confirmed the
source of the heterogeneity was from the study (data not
show). Many factors could be related to the heterogeneity,
the most important one is the definition of PAS the author
used [36]. Otherwise, the subjects involved in this study
were all female, pregnant, and young, and the anesthetic
technique was combined spinal epidural anesthesia, which
differed from the others. When omitting this study, homo-
geneity appeared and the pooled estimate became more
significant with a narrower confidence interval.
To our knowledge, this is the first meta-analysis to
explore the prophylactic effect of ondansetron on PAS.
Additionally, the original studies included in our meta-
analysis are all randomized, double-blinded and placebo-
controlled trials except one [3] without the mention of
blind, and all take PAS as primary outcome. Besides, the
negative association between ondansetron and the PAS
remained robust and significant in both subgroup and
sensitive analyses. Otherwise, we also compared ondanse-
tron with meperidine on the effect of PAS. Moreover, the
side effects and dose-dependent effect was also explored.
There are some potential limitations should be consid-
ered. Firstly, the test power, to some extent, is limited as
confined by the sample size. The individual study in this
meta-analysis has a relatively small sample with only one
study [17] more than 100 subjects. Secondly, the definitions
of PAS vary from each other. Three studies [3,13,17] used a
graded scale to evaluate the severity of shivering, and others
[14-16] defined PAS as some muscles shivering for mini-
mum 10 or 15 seconds. Thirdly, many included studies only
presented data about PAS but not simultaneous side effects
(nausea and vomiting, bradycardia, hypertension etc.). And
only three studies compared ondansetron with other anti-
shivering drugs, (meperidine, ketamine), we, therefore,
could not give a comprehensive evaluation of ondansetron.
Finally, dosages of ondansetron were not standard; either
4 mg or 8 mg was administrated in the individual study.
Some directions for future research should be drawn
out from current meta-analysis. The adequate sample,comprehensive side effects should be considered in future
research, and the effects of various dosage of ondansetron,
anesthetic technique and surgical setting on PAS should
also be explored. Furthermore, studies aimed to compare
ondansetron and other drugs should be conducted to
evaluate the clinical and economic efficacy of ondanse-
tron. Finally, the definition of PAS should be standardized.
Conclusions
Current meta-analysis demonstrated that ondansetron
has a preventive effect on PAS without a paralleled side
effect of bradycardia.
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